Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 20;24(4):271-278.
doi: 10.3779/j.issn.1009-3419.2021.101.08.

[Advances in Hyperprogressive Disease in Patients with Advanced Non-small Cell Lung Cancer Treated with Immunotherapy]

[Article in Chinese]
Shuyang Yao  1 , Kejian Shi  1 , Yi Zhang  1
Affiliations
Review

[Advances in Hyperprogressive Disease in Patients with Advanced Non-small Cell Lung Cancer Treated with Immunotherapy]

[Article in Chinese]
Shuyang Yao et al. Zhongguo Fei Ai Za Zhi. .

Abstract
in English, Chinese

Hyperprogressive disease (HPD) is a novel pattern of progression caused by immune checkpoint inhibitors (ICIs). It is characterized by a dramatic tumor surge and is associated with poor clinical outcomes. Up to now, the definition of HPD is still controversial across various studies. Although it has been indicated that HPD has related to multiple clinicopathological features and genetic alterations, it is lack of biomarker to predict its occurrence, and the potential mechanism remains unknown. This review is to summarize current data on HPD specialized in the field of non-small cell lung cancer. And we expect to provide helpful clinical strategies for oncologists using ICIs. .

【中文题目：晚期非小细胞肺癌免疫治疗超进展的研究进展】 【中文摘要：超进展（hyperprogressive disease, HPD）是一种由免疫检查点抑制剂（immune checkpoint inhibitors, ICIs）治疗导致的进展模式。它表现为肿瘤爆发式生长和极差的患者预后。目前各研究中HPD的定义不尽相同。虽然已经发现HPD与多种临床病理特点和基因类型有关，但目前仍没有可以准确预测它的肿瘤标志物，而且潜在的机制也尚在研究中。本文着眼于晚期非小细胞肺癌，对HPD的研究现状进行综述，以期给采用ICIs药物治疗患者的临床医生提供有益的参考 。 】 【中文关键词：肺肿瘤；超进展；免疫检查点抑制剂；免疫治疗】.

Keywords: Hyperprogressive disease; Immune checkpoint inhibitors; Immunotherapy; Lung neoplasms.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Zhou CC, Wang J, Bu H, et al. Chinese experts consensus on immune checkpoint inhibitors for non-small cell lung cancer (2019 version) Zhongguo Fei Ai Za Zhi. 2020;23(2):65–76. - PMC - PubMed
    2. 周 彩存, 王 洁, 步 宏, et al. 中国非小细胞肺癌免疫检查点抑制剂治疗专家共识(2019年版) 中国肺癌杂志. 2020;23(2):65–76. doi: 10.3779/j.issn.1009-3419.2020.02.01. - DOI - PubMed
    1. Gettinger S, Horn L, Jackman D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol. 2018;36(17):1675–1684. doi: 10.1200/JCO.2017.77.0412. - DOI - PubMed
    1. Rebuzzi SE, Leonetti A, Tiseo M, et al. Advances in the prediction of long-term effectiveness of immune checkpoint blockers for non-small-cell lung cancer. Immunotherapy. 2019;11(12):993–1003. doi: 10.2217/imt-2019-0107. - DOI - PubMed
    1. Galli G, Proto C, Signorelli D, et al. Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. Future Oncol. 2019;15(23):2743–2757. doi: 10.2217/fon-2019-0055. - DOI - PubMed
    1. Kim Y, Kim CH, Lee HY, et al. Comprehensive clinical and genetic characterization of hyperprogression based on volumetry in advanced non-small cell lung cancer treated with immune checkpoint inhibitor. J Thorac Oncol. 2019;14(9):1608–1618. doi: 10.1016/j.jtho.2019.05.033. - DOI - PubMed

MeSH terms

Substances